President Trump’s choice to lead the FDA faced some questions, but not many, about drug pricing, according to various press reports about the Senate committee hearing Thursday regarding the nomination of Stephen Hahn, MD, FASTRO, the chief medical officer of MD Anderson Cancer Center.
President Trump’s choice to lead the FDA faced some questions, but not many, about drug pricing, according to various press reports about the Senate committee hearing Thursday regarding the nomination of Stephen Hahn, MD, FASTRO, the chief medical officer of MD Anderson Cancer Center.
The issue of vaping, and whether he supports a ban on flavored products, was the primary focus; he demurred from specifics, saying he would defer to the White House, where a policy is under review.
In prepared testimony before the Senate’s Committee on Health, Education Labor and Pensions (HELP), Hahn said that, if confirmed, “I promise to be guided by the core values of integrity and transparency, and I promise to put the interests of the American people first.” He also stressed his scientific background and said he respected Congress.
Also on Wednesday, the Biosimilars Forum released a statement stressing how previous FDA commissioners—most notably Scott Gottlieb, MD—promoted biosimilars.
Past leaders “have recognized the urgent need for educating stakeholders and accelerating biosimilar uptake, given that patients and the US health care system at large could save up to $150 billion over the next decade with increased biosimilar use. It is critical that the FDA continue combating misinformation and anti-competitive practices surrounding biosimilars, as well as reforming regulatory processes to allow for increased competition in the market,” the forum said.
Eleven of the 25 approved biosimilars are currently on the market, noted the forum, which is supporting various pieces of legislation to promote biosimilars.
Stat News reported that Hahn did acknowledge the issue of high drug prices in response to questions from Senator Mike Braun, R-Indiana.
“Not a week goes by when I see a patient who doesn’t comment on the stress—‘financial toxicity’ is how people refer to it—of high prescription drug prices,” said Hahn, who said he supports “moving forward with action that makes sense.”
In addition, Hahn appeared noncommittal on the administration’s idea to allow certain drug imports from Canada. He did not commit to supporting individual importation proposal, but said he would be open to examining whether drug importation could be conducted safely.
Senator Lamar Alexander, R-Tennessee, the committee chairman, said a vote on the nomination is expected in early December.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.